Source: Benzinga

Centrexion Therapeutics: Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 American College of Rheumatology Annual Meeting and the 2019 American Academy of Physical Medicine and Rehabilitation Annual Assembly

BOSTON, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapies for the treatment of chronic pain, today announced it will present posters on CNTX-4975 at the 2019 American College of Rheumatology (ACR) Annual Meeting Conference taking place November 8-13, 2019 in Atlanta, Georgia and at the 2019 American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly taking place November 14-17, 2019 in San Antonio, Texas. Full abstracts are available online at acrabstracts.org. Details of the poster presentation are listed below.Title: Evaluation of Intra-articular CNTX-4975 in Subjects With Painful Bilateral Knee Osteoarthritis: Effects on Pain With Walking and Patient Impression of Change in PainSession Title: Osteoarthritis - Clinical Poster IAbstract Number: 1322Presentation Time: Monday, November 11, 9:00AM - 11:00AMLocation: Georgia World ...Full story available on Benzinga.com

Read full article ยป
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Jeffrey B. Kindler's photo - CEO of Centrexion

CEO

Jeffrey B. Kindler

CEO Approval Rating

90/100

Read more